Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 10 institutions in 1 country.
O CapdevilaAutoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
F MitjavilaAutoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
G EspinosaDepartment of Autoimmune Diseases, Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0003-1336-0163
L Caminal-MonteroGroup of Basic and Translational Research in Inflammatory Diseases, Departament of Internal Medicine, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-4044-8235
A Marín-BallvèDepartment of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
R González LeónDepartment of Internal Medicine, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
A CastroDepartment of Internal Medicine, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain.ORCID 0000-0001-5441-6333
J CanoraDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.ORCID 0000-0002-5231-9721
B PinillaDepartment of Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
E FonsecaDepartment of Internal Medicine, Hospital de Cabueñes, 33394 Gijón, Spain.
G Ruiz-IrastorzaAutoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, 48903 Barakaldo, Spain.ORCID 0000-0001-7788-1043
RELES, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine
Bellvitge University Hospital · ESBioCruces Health research Institute · ESHospital Clínic de Barcelona · ESHospital Clínico Universitario Lozano Blesa · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario De Cabueñes · ESHospital Universitario de Fuenlabrada · ESHospital Universitario Virgen del Rocío · ESHospital Universitari Sant Joan de Reus · ESInstituto de Investigación Sanitaria del Principado de Asturias · ES
Funding
Ruiz-Irastorza was supported by the Department of Education of the Basque Government (Grant number: IT 1512-22).
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. · full record | OpenQuestion